Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft-Versus-Host Disease

Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation volume 36, pages 343–348 (2005)Cite this article

Summary:

Methotrexate (MTX) is commonly used in the prophylaxis of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In order to evaluate the efficacy and safety of low-dose MTX treatment in patients with GVHD after allo-HSCT, 38 patients with acute GVHD (aGVHD), chronic GVHD (cGVHD) or GVHD post-donor lymphocyte infusion (post-DLI GVHD) after allo-HSCT received intravenous MTX at a dose of 5 or 10 mg every 5–7 days until a complete or partial response was seen, or there was treatment failure or intolerable side effects. The overall response rate was 94.7% (18/19 patients) in patients with aGVHD, 76.2% (16/21 patients) in patients with cGVHD and 2/2 in patients with post-DLI GVHD. The response rate for GVHD involving various organs was 100% in skin, 75% in gut, 55.6% in liver, 75% in mouth and 100% in the eye, among all enrolled patients. Side effects were minor. Short-term, low-dose MTX is a tolerable and an effective regimen for patients with aGVHD, cGVHD or post-DLI GVHD after allo-HSCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Greinix HT, Volc-Platzer B, Rabitsch W et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098–3104.

    CAS  PubMed  Google Scholar 

  2. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man: a clinicopathological study of 20 long-term Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  3. Lee SJ, Klein JP, Barrett J et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406–414.

    Article  CAS  PubMed  Google Scholar 

  4. Weisdorf D, Haak R, Blazar B et al. Treatment of moderate/severe acute graft versus host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024–1030.

    CAS  PubMed  Google Scholar 

  5. Sullivan KM, Witherspoon RP, Storb R et al. Alternating day cyclosporine and prednisone for treatment of high risk chronic graft versus host disease. Blood 1988; 72: 555–561.

    CAS  PubMed  Google Scholar 

  6. Sullivan KM, Witherspoon RP, Storb R et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft versus host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72: 546–554.

    CAS  PubMed  Google Scholar 

  7. Willenbacher W, Basara N, Blau IW et al. Treatment of steroid refractory acute and chronic graft versus host disease with daclizumab. Br J Haematol 2001; 112: 820–823.

    Article  CAS  PubMed  Google Scholar 

  8. Parker PM, Chao N, Nadamanee A et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86: 3604–3609.

    CAS  PubMed  Google Scholar 

  9. Mookerjee B, Altomonte V, Vogelsang G . Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 1999; 24: 517–520.

    Article  CAS  PubMed  Google Scholar 

  10. Storb R, Deeg HJ, Fisher L et al. Cyclosporine vs methotrexate for graft-versus-host disease prevention in patients given marrow graft for leukemia: long-term follow-up of three controlled trial. Blood 1988; 71: 293–298.

    CAS  PubMed  Google Scholar 

  11. Rinden O, Horowitz MM, Sondel P et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia. Blood 1993; 81: 1094–1101.

    Google Scholar 

  12. Gaziev D, Lucarelli G, Polchi P et al. A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease. Bone Marrow Transplant 2001; 27: 45–51.

    Article  CAS  PubMed  Google Scholar 

  13. Martin P, Bleyzac N, souillet G et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003; 32: 881–887.

    Article  CAS  PubMed  Google Scholar 

  14. Koga Y, Nagatoshi Y, Okamura J . Methotrexate vs cyclosporin A as single agent fro graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan. Bone Marrow Transplant 2003; 32: 171–176.

    Article  CAS  PubMed  Google Scholar 

  15. Huang XJ, Han W, Xu LP et al. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease. Chin Med J (Engl) 2004; 117: 1778–1785.

    Google Scholar 

  16. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. New Engl J Med 1975; 292: 832–843, 895–902.

    Article  CAS  PubMed  Google Scholar 

  17. Wingard JE, Piantadosi S, Vogelsang GB et al. Predictors of death from chronic graft versus host disease after bone marrow transplantation. Blood 1989; 74: 1428–1435.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Hematology, Peking University, People’ Hospital, Beijing, China

    X-J Huang, Q Jiang, H Chen, L Xu, D Liu, Y Chen, W Han, Y Zhang, K Liu & D Lu

Authors
  1. X-J Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Q Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to X-J Huang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, XJ., Jiang, Q., Chen, H. et al. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 36, 343–348 (2005). https://doi.org/10.1038/sj.bmt.1705034

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705034

Keywords

This article is cited by

Search

Advanced search

Quick links